Hamps Bio Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹60(117.65%)
Premium (ELP)
Hamps Bio Limited's has transitioned to a publicly listed entity following its IPO debut on Dec 20, 2024 at the BSE exchange. The public offering successfully raised 12,20,000 Shares, consisting of 12,20,000 Sharesin new capital.
The IPO featured a competitive price range of ₹51 to ₹51 and minimum application size of 2000 shares. Market reception was evidenced through subscription activity between Dec 13, 2024 and Dec 17, 2024, reflecting investor appetite for the offering.
Allotment of shares was completed on Dec 18, 2024, distributing equity to successful applicants. The listing marked the beginning of the company's journey as a publicly traded corporation, subject to market dynamics and regulatory oversight.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Hamps Bio Limited, incorporated in 2007, is engaged in marketing and distributing pharmaceutical products under the “Hamps” brand and freeze-dried and frozen FMCG items under the “FzyEzy” brand. Its pharmaceutical portfolio includes tablets, syrups, capsules, injectables, and powders, distributed across eight Indian states and union territories through 50+ distributors and online platforms such as Amazon, Flipkart, and Jio Mart. The company’s FMCG division offers freeze-dried and frozen products like strawberry, mango, and beet powders for both B2B and B2C markets, including contract manufacturing. With a portfolio of 180+ products across both verticals, Hamps Bio serves domestic and international markets and employed 78 people as of October 31, 2024.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Expert Leadership and Industry Experience: A seasoned and knowledgeable management team drives strategic growth, operational efficiency, and long-term business vision.
- Expansive Distribution Network with E-Retailing: Strong presence across 50+ distributors combined with availability on major e-commerce platforms such as Amazon and Flipkart ensures wide market reach and accessibility.
- Diverse Product Portfolio: With over 180 products spanning pharmaceuticals and FMCG categories, the company caters to a broad customer base across both domestic and international markets.
- Outstanding Litigation: Pending legal disputes may pose financial liabilities and harm the company’s reputation and business operations if outcomes are not favorable.
- Dependence on Third-Party Manufacturing: Heavy reliance on external manufacturers for pharmaceutical products exposes the company to potential supply chain disruptions, quality issues, and compliance risks.
- Single-Region Manufacturing Facility: Concentrating freeze-dried and frozen product manufacturing in Ankleshwar, Gujarat increases vulnerability to regional disruptions, which could adversely impact production and overall business continuity.
- Herrik Shah
- Shrenik Shah
- Pallavi Shah
- Mitali Shah
- Herrik Shah HUF
- Shrenik Shah HUF
Hamps Bio Limited
Bigshare Services Private Limited